Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Value

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon May 07, 2021 4:45pm

231 Views

Post# 33155932

RE:RE:RE:Value

Doccole wrote: What kind of number? Do you value?

Let me put it this way ... my valuation (if the company were sold) is embarrasingly higher than the present market cap.

Keep in mind that I don't know if my assumptions are the same assumptions the negotiating parties would be using. I can bet you that they are not likely using these assumptions yet.

I also think we need the rest of 2021 to prove these assumptions and show a much improved financial model - one that any Big Pharma would need to accept or would find difficult to argue against during negotiations.

Then ... I do believe we're talking a few billion (my opinion and my assumptions only)

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta